CBM FX
Alternative Names: CBM-FXLatest Information Update: 02 Jan 2023
At a glance
- Originator CellionBioMed
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics
- Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 29 Dec 2022 CBM FX is still in phase I tria for Systemic lupus erythematosus in South Korea (CellionBioMed pipeline, December 2022)
- 29 Dec 2022 CBM FX is still in phase I trial for Psoriasis in South Korea(CellionBioMed pipeline, December 2022)
- 29 Dec 2022 CBM FX is still in phase I trial for Rheumatoid arthritis in South Korea (CellionBioMed pipeline, December 2022)